newsfilter
← Latest News
GlobeNewswire·

LB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

LBRX
  • LB Pharmaceuticals appointed Susan G. Kozauer as Chief Medical Officer & Joseph Miller as Chief Financial Officer to strengthen leadership.
  • The company completed a private placement in July 2026, raising $150 million with net proceeds of approximately $140.9 million to fund LB-102 expansion & general corporate purposes.
  • Cash, cash equivalents, & short-term investments totaled $403.8 million as of September 30, 2026, providing a runway beyond Q2 2029.
  • Topline data from the pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia is expected in the first half of 2027, with a pre-NDA FDA meeting anticipated in the second half of 2027.
  • New preclinical data supporting LB-102's bimodal mechanism of action was presented at the 39th ECNP Congress in October 2026.
  • The Phase 2 ILLUMINATE-1 trial for bipolar depression continues enrollment with topline data expected in Q1 2028.
  • A Phase 2 trial for adjunctive treatment of MDD is expected to initiate in early 2027 with topline data expected in the first half of 2029.
  • Research & development expenses were $51.5 million for the three months ended September 30, 2026, compared to $2.4 million in the same period last year.
  • General & administrative expenses were $11.0 million for the three months ended September 30, 2026, compared to $2.8 million in the same period last year.
  • The company reported a net loss of $59.1 million for the three months ended September 30, 2026, & $129.7 million for the nine months ended September 30, 2026.
  • LB-102 remains the lead asset as a novel benzamide antipsychotic candidate targeting schizophrenia, bipolar depression, & major depressive disorder.
Company
LB Pharmaceuticals Inc
Keywords
Nasdaq:LBRX, LB Pharmaceuticals Inc